SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris-Reference-Cited by-同舟云学术

SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris

Published:2023-08 Issue:8 Volume:143 Page:1601-1604
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Fenizia Claudio^ORCID,Moltrasio Chiara^ORCID,Ottobrini Luisa^ORCID,Utyro Olga^ORCID,Genovese Giovanni^ORCID,Vanetti Claudia^ORCID,Trabattoni Daria^ORCID,Marzano Angelo V.^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference15 articles.

1. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy;Apostolidis;Nat Med,2021

2. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients;Avouac;Rheumatology (Oxford),2022

3. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases;Baker;Clin Exp Immunol,2020

4. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer;Bange;Nat Med,2021

5. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: a narrative review;Beyzaee;Dermatol Ther,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serological response to SARS‐CoV‐2 vaccination in patients with immunobullous diseases;JEADV Clinical Practice;2024-06-19

2. Off‐label use of rituximab for dermatologic conditions: A single center review;JEADV Clinical Practice;2024-04

3. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine;Frontiers in Immunology;2024-01-04

4. Rituximab treatment for refractory and moderate-to-severe pemphigus patients in the pandemic era: A single-center retrospective study;Dermatologica Sinica;2024-01

5. Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”;Vaccines;2023-09-12